Bristol-Myers Squibb Raises FY2026 Adj EPS Guidance from $6.05-$6.35 to $6.75-$7.00 vs $6.34 Est; Raises FY2026 Sales Guidance from $46.000B

Bristol-Myers Squibb (NYSE: BMY ) raises FY2026 Adj EPS guidance from $6.05-$6.35 to $6.75-$7.00 vs $6.34 analyst estimate. Raises FY2026 sales outlook from $46.000 billion-$47.500 billion to $49.000 billion-$50.000 billion vs $47.472 billion estimate.